In-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine: Correlation with COVID-19 severity from a cohort study in Qatar
<h3>Background</h3><p dir="ltr">Serological assays targeting antibodies against key viral proteins, including the Spike (S1), Receptor Binding Domain (RBD), and Nucleocapsid, play a critical role in understanding immunity and supporting diagnostic efforts during COVID-19...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , , , , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513550746124288 |
|---|---|
| author | Nishant N. Vaikath (2901785) |
| author2 | Maryam Ali Al-Nesf (13040248) Nour Majbour (3528548) Houari B. Abdesselem (14152827) Vijay Gupta (209146) Ilham Bensmail (12204845) Ilham Y. Abdi (14778898) Khalifa Ahmed Elmagarmid (20923799) Shadah Shabani (20923802) Indulekha P. Sudhakaran (9611154) Simona S. Ghanem (12267227) Mohammed Al-Maadheed (12204886) Vidya Mohamed-Ali (12204895) Jonathan M. Blackburn (699590) Julie Decock (44558) Omar M.A. El-Agnaf (18595255) |
| author2_role | author author author author author author author author author author author author author author author |
| author_facet | Nishant N. Vaikath (2901785) Maryam Ali Al-Nesf (13040248) Nour Majbour (3528548) Houari B. Abdesselem (14152827) Vijay Gupta (209146) Ilham Bensmail (12204845) Ilham Y. Abdi (14778898) Khalifa Ahmed Elmagarmid (20923799) Shadah Shabani (20923802) Indulekha P. Sudhakaran (9611154) Simona S. Ghanem (12267227) Mohammed Al-Maadheed (12204886) Vidya Mohamed-Ali (12204895) Jonathan M. Blackburn (699590) Julie Decock (44558) Omar M.A. El-Agnaf (18595255) |
| author_role | author |
| dc.creator.none.fl_str_mv | Nishant N. Vaikath (2901785) Maryam Ali Al-Nesf (13040248) Nour Majbour (3528548) Houari B. Abdesselem (14152827) Vijay Gupta (209146) Ilham Bensmail (12204845) Ilham Y. Abdi (14778898) Khalifa Ahmed Elmagarmid (20923799) Shadah Shabani (20923802) Indulekha P. Sudhakaran (9611154) Simona S. Ghanem (12267227) Mohammed Al-Maadheed (12204886) Vidya Mohamed-Ali (12204895) Jonathan M. Blackburn (699590) Julie Decock (44558) Omar M.A. El-Agnaf (18595255) |
| dc.date.none.fl_str_mv | 2025-03-20T18:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.jiph.2025.102744 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/In-house_assays_for_detecting_anti-SARS-CoV-2_antibodies_in_serum_and_urine_Correlation_with_COVID-19_severity_from_a_cohort_study_in_Qatar/28647743 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Microbiology Biomedical and clinical sciences Immunology Health sciences Epidemiology Public health COVID-19 SARS-CoV-2 IgM and IgG Neutralization assay Sengenics Urine diagnostics Serological assays |
| dc.title.none.fl_str_mv | In-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine: Correlation with COVID-19 severity from a cohort study in Qatar |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr">Serological assays targeting antibodies against key viral proteins, including the Spike (S1), Receptor Binding Domain (RBD), and Nucleocapsid, play a critical role in understanding immunity and supporting diagnostic efforts during COVID-19 pandemic, and afterward. This study aimed to develop and validate in-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine.</p><h3>Methods</h3><p dir="ltr">ELISA-based assay was developed to detect IgG and IgM antibodies against SARS-CoV-2. The assay was examined in serum and urine samples of two different cohort of patients affected by COVID-19 disease with different severity and compared to age and sex matched control group. Neutralizing antibody activity was evaluated using an RBD-ACE2 binding inhibition assay. Additionally, a Sengenics protein microarray platform was employed to assess epitope-specific antibody responses.</p><h3>Results</h3><p dir="ltr">The in-house ELISA assay reliably detected antibodies in both 163 serum and 64 urine samples compared to 50 serum samples from healthy control, with strong correlations observed between antibody levels in the two biofluids. Neutralizing antibody levels correlated positively with disease severity, highlighting their clinical relevance. The performance of the in-house assays was comparable to commercial kits, and the Sengenics microarray provided detailed insights into antibody profiles, identifying dominant epitopes within the Nucleocapsid core domain and RBD.</p><h3>Conclusions</h3><p dir="ltr">The developed in-house assay demonstrated robust performance and versatility, offering a cost-effective and scalable alternative to commercial kits. Their ability to detect antibodies in both serum and urine highlighted their potential as non-invasive diagnostic tools. These findings contribute to advancing sero-diagnostic capabilities, improving understanding of immune responses to SARS-CoV-2, and supporting global efforts to monitor and manage COVID-19 effectively.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Infection and Public Health<br>License: <a href="https://creativecommons.org/licenses/by/4.0/deed.en" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.jiph.2025.102744" target="_blank">https://dx.doi.org/10.1016/j.jiph.2025.102744</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_a9bff52684ed5e69c51ae064ecf439ad |
| identifier_str_mv | 10.1016/j.jiph.2025.102744 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/28647743 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | In-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine: Correlation with COVID-19 severity from a cohort study in QatarNishant N. Vaikath (2901785)Maryam Ali Al-Nesf (13040248)Nour Majbour (3528548)Houari B. Abdesselem (14152827)Vijay Gupta (209146)Ilham Bensmail (12204845)Ilham Y. Abdi (14778898)Khalifa Ahmed Elmagarmid (20923799)Shadah Shabani (20923802)Indulekha P. Sudhakaran (9611154)Simona S. Ghanem (12267227)Mohammed Al-Maadheed (12204886)Vidya Mohamed-Ali (12204895)Jonathan M. Blackburn (699590)Julie Decock (44558)Omar M.A. El-Agnaf (18595255)Biological sciencesMicrobiologyBiomedical and clinical sciencesImmunologyHealth sciencesEpidemiologyPublic healthCOVID-19SARS-CoV-2IgM and IgGNeutralization assaySengenicsUrine diagnosticsSerological assays<h3>Background</h3><p dir="ltr">Serological assays targeting antibodies against key viral proteins, including the Spike (S1), Receptor Binding Domain (RBD), and Nucleocapsid, play a critical role in understanding immunity and supporting diagnostic efforts during COVID-19 pandemic, and afterward. This study aimed to develop and validate in-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine.</p><h3>Methods</h3><p dir="ltr">ELISA-based assay was developed to detect IgG and IgM antibodies against SARS-CoV-2. The assay was examined in serum and urine samples of two different cohort of patients affected by COVID-19 disease with different severity and compared to age and sex matched control group. Neutralizing antibody activity was evaluated using an RBD-ACE2 binding inhibition assay. Additionally, a Sengenics protein microarray platform was employed to assess epitope-specific antibody responses.</p><h3>Results</h3><p dir="ltr">The in-house ELISA assay reliably detected antibodies in both 163 serum and 64 urine samples compared to 50 serum samples from healthy control, with strong correlations observed between antibody levels in the two biofluids. Neutralizing antibody levels correlated positively with disease severity, highlighting their clinical relevance. The performance of the in-house assays was comparable to commercial kits, and the Sengenics microarray provided detailed insights into antibody profiles, identifying dominant epitopes within the Nucleocapsid core domain and RBD.</p><h3>Conclusions</h3><p dir="ltr">The developed in-house assay demonstrated robust performance and versatility, offering a cost-effective and scalable alternative to commercial kits. Their ability to detect antibodies in both serum and urine highlighted their potential as non-invasive diagnostic tools. These findings contribute to advancing sero-diagnostic capabilities, improving understanding of immune responses to SARS-CoV-2, and supporting global efforts to monitor and manage COVID-19 effectively.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Infection and Public Health<br>License: <a href="https://creativecommons.org/licenses/by/4.0/deed.en" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.jiph.2025.102744" target="_blank">https://dx.doi.org/10.1016/j.jiph.2025.102744</a></p>2025-03-20T18:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.jiph.2025.102744https://figshare.com/articles/journal_contribution/In-house_assays_for_detecting_anti-SARS-CoV-2_antibodies_in_serum_and_urine_Correlation_with_COVID-19_severity_from_a_cohort_study_in_Qatar/28647743CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/286477432025-03-20T18:00:00Z |
| spellingShingle | In-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine: Correlation with COVID-19 severity from a cohort study in Qatar Nishant N. Vaikath (2901785) Biological sciences Microbiology Biomedical and clinical sciences Immunology Health sciences Epidemiology Public health COVID-19 SARS-CoV-2 IgM and IgG Neutralization assay Sengenics Urine diagnostics Serological assays |
| status_str | publishedVersion |
| title | In-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine: Correlation with COVID-19 severity from a cohort study in Qatar |
| title_full | In-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine: Correlation with COVID-19 severity from a cohort study in Qatar |
| title_fullStr | In-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine: Correlation with COVID-19 severity from a cohort study in Qatar |
| title_full_unstemmed | In-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine: Correlation with COVID-19 severity from a cohort study in Qatar |
| title_short | In-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine: Correlation with COVID-19 severity from a cohort study in Qatar |
| title_sort | In-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine: Correlation with COVID-19 severity from a cohort study in Qatar |
| topic | Biological sciences Microbiology Biomedical and clinical sciences Immunology Health sciences Epidemiology Public health COVID-19 SARS-CoV-2 IgM and IgG Neutralization assay Sengenics Urine diagnostics Serological assays |